[Comment] Is chemotherapy still needed in all patients with mismatch repair-deficient advanced or recurrent endometrial cancer?
Source 柳叶刀 Lancetjust now
Summary
Around a quarter of advanced or recurrent endometrial carcinomas are mismatch repair deficient (dMMR).1 Addition of a PD-1 or PD-L1 inhibitor to carboplatin pl…
We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.
Open original- Desk
- Health
- Region
- United Kingdom
- Language
- English
- Item ID
- health-cfd46a8e
Comments 0 comments
No comments yet. Be the first.